Latest news
Cadrenal Therapeutics Highlights CAD-1005 as Dual-Indication 12-LOX Inhibitor for HIT and CSA-AKI Following Competing Trial Failure - Quiver QuantitativeQuiver Quantitative · Mon, 03 Aug 2026 12:44:00 GMTCAD-1005 Phase 2 Data Show >25% Absolute Reduction in Thrombotic Events - Stock TitanStock Titan · Mon, 03 Aug 2026 12:30:00 GMT